Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, Kohl C, Rey M, Studer R, Vezzali E, Hess P, Clozel M, Steiner B, Bolli MH, Nayler O.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.370.

2.

A chromosomal region on ECA13 is associated with maxillary prognathism in horses.

Signer-Hasler H, Neuditschko M, Koch C, Froidevaux S, Flury C, Burger D, Leeb T, Rieder S.

PLoS One. 2014 Jan 21;9(1):e86607. doi: 10.1371/journal.pone.0086607. eCollection 2014.

3.

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M.

J Pharmacol Exp Ther. 2011 May;337(2):547-56. doi: 10.1124/jpet.110.176487. Epub 2011 Feb 23.

PMID:
21345969
4.

MSH radiopeptides for targeting melanoma metastases.

Eberle AN, Bapst JP, Calame M, Tanner H, Froidevaux S.

Adv Exp Med Biol. 2010;681:133-42. doi: 10.1007/978-1-4419-6354-3_11. Review.

PMID:
21222266
5.

Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.

Bapst JP, Froidevaux S, Calame M, Tanner H, Eberle AN.

J Recept Signal Transduct Res. 2007;27(5-6):383-409.

PMID:
18097939
6.
7.
8.

A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.

Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN.

J Nucl Med. 2004 Jan;45(1):116-23.

9.
10.

DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions.

Froidevaux S, Calame-Christe M, Sumanovski L, Tanner H, Eberle AN.

Ann N Y Acad Sci. 2003 Jun;994:378-83.

PMID:
12851339
11.

Homologous regulation of melanocortin-1 receptor (MC1R) expression in melanoma tumor cells in vivo.

Froidevaux S, Eberle AN.

J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):111-21.

PMID:
12503610
12.

A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis.

Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN.

J Nucl Med. 2002 Dec;43(12):1699-706.

13.

Somatostatin analogs and radiopeptides in cancer therapy.

Froidevaux S, Eberle AN.

Biopolymers. 2002;66(3):161-83. Review.

PMID:
12385036
14.

Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.

Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, Eisenwiener K, Beglinger C, Mäcke HR.

Int J Cancer. 2002 Apr 20;98(6):930-7.

15.

Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.

Schwab RE, Froidevaux S, Paku S, Tejeda M, Szende B, Pap A, Beglinger C, Eberle AN, Kéri G.

Anticancer Res. 2001 Jan-Feb;21(1A):71-5.

PMID:
11299792
16.

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.

Froidevaux S, Heppeler A, Eberle AN, Meier AM, Häusler M, Beglinger C, Béhé M, Powell P, Mäcke HR.

Endocrinology. 2000 Sep;141(9):3304-12.

PMID:
10965902
17.

Receptor targeting for tumor localisation and therapy with radiopeptides.

Heppeler A, Froidevaux S, Eberle AN, Maecke HR.

Curr Med Chem. 2000 Sep;7(9):971-94. Review.

PMID:
10911025
18.

Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.

Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN.

Cancer Res. 1999 Aug 1;59(15):3652-7.

19.

Characterization of transferrin receptor in an immortalized cell line of rat brain endothelial cells, RBE4.

Huwyler J, Froidevaux S, Roux F, Eberle AN.

J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):729-39.

PMID:
10071796
20.

A combinatorial peptoid library for the identification of novel MSH and GRP/bombesin receptor ligands.

Heizmann G, Hildebrand P, Tanner H, Ketterer S, Pansky A, Froidevaux S, Beglinger C, Eberle AN.

J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):449-66.

PMID:
10071777
21.

A microplate binding assay for the somatostatin type-2 receptor (SSTR2).

Froidevaux S, Meier M, Häusler M, Mäcke H, Beglinger C, Eberle AN.

J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):167-80.

PMID:
10071756
22.

Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice.

Pourtier-Manzanedo A, Didier A, Froidevaux S, Loor F.

Toxicology. 1995 May 23;99(3):207-17.

PMID:
7610467
24.

gld and lpr hematopoietic cell transfers: common and different serological features of the C57BL/6 chimeras.

Velin D, Goettelfinger P, Froidevaux S, Loor F.

Cell Immunol. 1993 May;148(2):331-45.

PMID:
8098670
25.
26.
27.

Adoptive transfer of the gld syndrome in double congenic nude lpr mice.

Froidevaux S, Rosenblatt N, Loor F.

Autoimmunity. 1992;12(2):107-15.

PMID:
1617109
28.

A quick procedure for identifying doubly homozygous immunodeficient scid beige mice.

Froidevaux S, Loor F.

J Immunol Methods. 1991 Mar 21;137(2):275-9.

PMID:
2013702
29.

Different nature of the proliferation defects of GLD, LPR and MEV C57BL/6 mouse lymphoid cells.

Froidevaux S, Kuntz L, Velin D, Loor F.

Autoimmunity. 1991;10(3):233-40.

PMID:
1756226

Supplemental Content

Loading ...
Support Center